Please assess the completion status of the following clinical trial:

Trial Title: A Phase II Trial to Assess Hemodynamic Effects of Istaroxime in Pts With Worsening HF and Reduced LV Systolic Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Signing of a written informed consent form.~* Male or female patients aged between 18 and 85 years.~* Negative pregnancy test at screening, for women of childbearing potential.~* Body weight less or equal to 100 kg.~* Blood pressure not more than SAP=150 or DAP=90 mmHg.~* Heart rate in the range of 60-110 bpm~* Adequate Echo window available.~* Hospital admission to a monitored bed with a primary diagnosis of worsening of heart failure and LV Ejection Fraction less or equal to 35% documented by 2D-Echocardiogram, or radionuclide angiography or LV angiogram within 6 months prior to screening or at hospitalization.~* the clinical condition of the patient are stabilized within 48 hours from hospitalization and do not require continuous iv drug treatments~* no need for additional new oral treatments or any intravenous treatment administration over the following 8 hours is foreseen~Randomisation period inclusion criteria:~* Any residual sign of heart failure (e.g.: Jugular Venous Distension, and/or Rales and/or Peripheral Oedema) associated with a PCWP more or equal to 20 mmHg,~* The last three consecutive determinations of PCWP, obtained during the stabilization period, have to be in a maximum range of variability of 10%.~Exclusion Criteria:~* Ongoing treatment with oral or intravenous inotropes and/or inodilators.~* Patient treated with digoxin within the last week, can be randomised if the plasma concentration of digoxin are tested before randomisation and its value will be less than 0.5 ng/ml.~* Intermittent inotropes administration within 2 weeks.~* Symptoms of Heart Failure at randomization e.g.: dyspnoea~* Systolic blood pressure \< 90 mmHg.~* Atrial fibrillation within 2 weeks.~* Left Ventricular Bundle Branch Block~* Cardiogenic shock or mechanical ventilation.~* Creatinine level \> 3.0 mg/dl or requiring dialysis treatment.~* Left ventricular failure primarily from uncorrected obstructive valvular disease, hypertrophic obstructive cardiomyopathy, restrictive/obstructive cardiomyopathy, uncorrected thyroid disease, known acute myocarditis, known amyloid cardiomyopathy.~* Artificial heart valve.~* Electrical device implanted (ICD, CRT)~* Evidence of acute coronary syndrome within 3 months.~* History of stroke or transient ischemic attack in the 6 months prior to screening.~* History of sustained ventricular tachycardia.~* Coronary by-pass grafting or PTCA within the last 30 days~* INR \> 1.5.~* Status post successful cardiac resuscitation.~* Serum K \< 3.5 mEq/l or \> 5.3 mEq/l just prior to treatment.~* ALT, AST \> 3 times the upper normal limit just prior to treatment.~* Hemoglobin \< 10 g/dl (either gender) just prior to treatment.~* Other clinically significant laboratory or medical conditions, which in the opinion of the Investigator make the patient unsuitable for evaluation in the study.~* Anticipated survival of less than 2 months for concomitant diseases.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Istaroxime dose of 0.5 microgram/kg body weight/minute of iv infusion for six ours
- 2 (Type: EXPERIMENTAL): Istaroxime dose of 1.0 microgram/kg body weight/minute of iv infusion for six ours
- 3 (Type: EXPERIMENTAL): Istaroxime dose of 1.5 microgram/kg body weight/minute of iv infusion for six ours
- 4 (Type: PLACEBO_COMPARATOR): Placebo iv infusion for six ours

Based on this trial design, predict the completion outcome and termination type (if applicable).